Ra Medical Systems, Inc.: insider trades · United States · SEC (Form 4)

About Ra Medical Systems, Inc.

Ra Medical Systems, Inc. is a U.S. medical device company that has evolved from an excimer-laser platform developer into an electrophysiology-focused business under the Catheter Precision identity. The company was founded in 2002 in California and later reincorporated in Delaware in 2018. Its public equity history has been tied to the U.S. NYSE American market under the ticker RMED, placing it in the small-cap medtech segment of the United States. Historically, Ra Medical built its business around advanced excimer laser technology for vascular and dermatological applications. Its legacy portfolio included the DABRA laser system for peripheral artery disease and the Pharos laser for skin conditions such as psoriasis and related inflammatory dermatological diseases. Over the past several years, however, the company has undergone a major strategic transition. In 2021 it sold its dermatology business, and in 2023 it completed a merger with Catheter Precision, a privately held company focused on electrophysiology solutions. That transaction fundamentally changed the company’s operating profile and long-term strategic narrative. Today, the company’s core focus is on products used in electrophysiology procedures and cardiac rhythm management workflows. Its main offering is VIVO, a non-invasive 3D imaging system designed to help localize the origin of idiopathic ventricular arrhythmias before EP procedures. The portfolio also includes adjunct products such as LockeT. This positions the company in a specialized medtech niche where clinical differentiation, physician adoption, and hospital workflow integration matter more than large-scale manufacturing volume. Competitively, Ra Medical operates in a market crowded with much larger and better-capitalized device manufacturers, particularly in cardiology, mapping, and ablation-related technologies. As a result, the company’s success depends on clinical validation, regulatory execution, reimbursement dynamics, and effective commercial adoption. Its smaller scale is a disadvantage in distribution and R&D spend, but it may also allow for focused development in specific use cases that are not fully addressed by larger rivals. Geographically, the company is based in the United States and primarily addresses the domestic market through hospitals, electrophysiology labs, and specialist physicians. Recent corporate milestones include the merger with Catheter Precision, the continued shift away from legacy laser businesses, and the commercialization ramp of VIVO and related products. For investors, RMED should be viewed as a U.S.-listed micro/small-cap medtech story with high execution risk but meaningful product-focused upside if clinical and commercial adoption continues to improve.